Company intelligence / Profile preview

Tianjin KingYork Group

Tianjin, Tianjin, China

Ownership: Private
Development stage: Other

Overview

Tianjin KingYork Group operates subsidiaries focused on the manufacture and distribution of small-volume parenteral solutions, corticosteroid and amino acid APIs, and finished preparations. Its products include approved drugs for allergy (chlorpheniramine maleate), edema (sorbitol), and several API drugs. It is recognized as a national high-tech enterprise and pharmaceutical tech leader in China, with a significant footprint in the corticosteroid sector.

Therapeutic areas: CardiovascularImmunologyInfectious Diseases
Modalities: Small moleculeDrug
Industry: Biotech

Beyond the preview

Go deeper on Tianjin KingYork Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianjin KingYork Group.

Explore the full profile